MX2023014658A - Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2. - Google Patents
Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2.Info
- Publication number
- MX2023014658A MX2023014658A MX2023014658A MX2023014658A MX2023014658A MX 2023014658 A MX2023014658 A MX 2023014658A MX 2023014658 A MX2023014658 A MX 2023014658A MX 2023014658 A MX2023014658 A MX 2023014658A MX 2023014658 A MX2023014658 A MX 2023014658A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- treating chronic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209624P | 2021-06-11 | 2021-06-11 | |
| PCT/US2022/032979 WO2022261417A1 (en) | 2021-06-11 | 2022-06-10 | Method for treating chronic obstructive pulmonary disease with an st2 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014658A true MX2023014658A (es) | 2024-01-12 |
Family
ID=82458702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014658A MX2023014658A (es) | 2021-06-11 | 2022-06-10 | Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228638A1 (enExample) |
| EP (1) | EP4352101A1 (enExample) |
| JP (1) | JP2024522175A (enExample) |
| KR (1) | KR20240019831A (enExample) |
| CN (1) | CN117980333A (enExample) |
| AU (1) | AU2022289017A1 (enExample) |
| BR (1) | BR112023025863A2 (enExample) |
| CA (1) | CA3221924A1 (enExample) |
| IL (1) | IL308597A (enExample) |
| MX (1) | MX2023014658A (enExample) |
| TW (1) | TW202317622A (enExample) |
| WO (1) | WO2022261417A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| CA3263546A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Limited | ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
| CN122121878A (zh) * | 2023-09-06 | 2026-05-29 | 维罗纳制药有限公司 | 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀 |
| TW202540173A (zh) * | 2024-04-04 | 2025-10-16 | 英商梅迪繆思有限公司 | 治療及選擇對象之方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
-
2022
- 2022-06-10 CA CA3221924A patent/CA3221924A1/en active Pending
- 2022-06-10 IL IL308597A patent/IL308597A/en unknown
- 2022-06-10 EP EP22738817.0A patent/EP4352101A1/en active Pending
- 2022-06-10 AU AU2022289017A patent/AU2022289017A1/en active Pending
- 2022-06-10 KR KR1020247001146A patent/KR20240019831A/ko active Pending
- 2022-06-10 CN CN202280040921.3A patent/CN117980333A/zh active Pending
- 2022-06-10 MX MX2023014658A patent/MX2023014658A/es unknown
- 2022-06-10 WO PCT/US2022/032979 patent/WO2022261417A1/en not_active Ceased
- 2022-06-10 JP JP2023575701A patent/JP2024522175A/ja active Pending
- 2022-06-10 TW TW111121634A patent/TW202317622A/zh unknown
- 2022-06-10 BR BR112023025863A patent/BR112023025863A2/pt unknown
-
2023
- 2023-12-04 US US18/528,122 patent/US20240228638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202317622A (zh) | 2023-05-01 |
| BR112023025863A2 (pt) | 2024-03-05 |
| IL308597A (en) | 2024-01-01 |
| CA3221924A1 (en) | 2022-12-15 |
| AU2022289017A1 (en) | 2023-11-30 |
| AU2022289017A9 (en) | 2023-12-07 |
| KR20240019831A (ko) | 2024-02-14 |
| US20240228638A1 (en) | 2024-07-11 |
| EP4352101A1 (en) | 2024-04-17 |
| JP2024522175A (ja) | 2024-06-11 |
| CN117980333A (zh) | 2024-05-03 |
| WO2022261417A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Léauté‐Labrèze et al. | Infantile haemangioma: part II. Risks, complications and treatment | |
| BR112023025863A2 (pt) | Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2 | |
| Evans et al. | Management of postoperative pain in maxillofacial surgery | |
| Ramirez-Fort et al. | Continuous versus intermittent therapy for moderate-to-severe psoriasis | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| Distler et al. | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis | |
| WO2003079979A3 (en) | Method for treating congestive heart failure | |
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| Hosalli et al. | Comparative efficacy of different doses of fentanyl on cardiovascular responses to laryngoscopy and tracheal intubation | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| Hong et al. | Characteristics of acromegaly in Korea with a literature review | |
| MX2023012455A (es) | Golexanolona para usarse en el tratamiento de la fatiga o deterioro cognitivo en pacientes con enfermedad hepatica. | |
| Rosenberg et al. | Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy | |
| Bali et al. | Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| WO2005009217A3 (en) | Diagnosis of pre-cancerous conditions using pcdgf agents | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| Kim et al. | Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients | |
| WO2025080877A3 (en) | Therapeutic peptides | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| Kong et al. | Completing the picture: the impact of multimodal analgesia on post-operative outcomes in cleft-related orthognathic surgery | |
| EP3206694B1 (en) | Use of neridronic acid or of its salt for the treatment of osteoarthrosis |